Overview

Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Nevirapine